Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Next Previous
X
Search
Trial Profile

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Duvelisib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Etoposide; Prednisone; Vincristine
  • Indications Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 07 Sep 2021 Status changed from not yet recruiting to recruiting.
    • 19 Jul 2021 Planned initiation date changed from 1 Jun 2021 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top